Update on Antiretroviral Regimens for Treating and Preventing HIV Infection and Update on Early Infant Diagnosis of HIV: Interim Guidance. WHO. (2018)

immage

Update on antiretroviral regimens for treating and preventing HIV infection: Since 2016, WHO has recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first- line antiretroviral therapy (ART) regimen for adults and adolescents. WHO recommended dolutegravir (DTG) as an alternative option to EFV for first-line ART because of the uncertainty regarding the safety and efficacy of DTG during pregnancy and among people living with HIV receiving rifampicin-based tuberculosis (TB) treatment.

 

Update on early infant diagnosis of HIV: In 2016, WHO recommended that HIV virological testing be used to diagnose HIV infection among infants and children younger than 18 months and that ART be started without delay while a second specimen is collected to confirm the initial positive virological test result.

 

Keywords: HIV, ART, diagnosis, treatment

 

 

Download Publication

Undetectable = Untransmittable — Public Health and HIV Viral Load Suppression. UNAIDS. (2018)

immage

Twenty years of evidence demonstrates that HIV treatment is highly effective in reducing the transmission of HIV. People living with HIV on antiretroviral therapy who have an undetectable level of HIV in their blood have a negligible risk of transmitting HIV sexually.

 


Keywords: HIV, ART, PLHIV, treatment

 

 

Download Publication

An Informal Consultation on Validation of Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis. WHO Office of the Representative to Malaysia, Brunei Darussalam and Singapore. (2018)

immage

The consultation was convened in Malaysia (Putrajaya, 27 to 28 February 2018) by the Malaysian Ministry of Health and WHO to discuss potential approaches for validation of mother-to-child transmission of hepatitis B inviting national and international experts.

 

 


Keywords: HIV infections, child, maternal health, hepatitis B, syphilis

 

 

Download Publication

Global Hepatitis Report, 2017. WHO. (2017)

immage

This WHO Global hepatitis report describes, for the first time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.

 

The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and saving lives between 2015 and 2030. 


Keywords: HIV, HCV, HBV, prevention, testing, treatment

 


Download Global Hepatitis Report 2017

 

Download Executive Summary

 

Regional Action Plan for Viral Hepatitis in South-East Asia, 2016–2021. WHO, Regional Office for South-East Asia. (2017)

immage

Viral hepatitis now ranks as the seventh leading cause of mortality worldwide. Although mortality due to communicable diseases has declined globally, the absolute burden and relative ranking of viral hepatitis as a cause of mortality has increased between 1990 and 2013.

 

Viral hepatitis causes at least as many, if not more, deaths annually compared with TB, AIDS, or malaria. Mortality due to viral hepatitis is increasing with time, while that due to TB, HIV and malaria is declining. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for more than 90% of viral hepatitis-related deaths and disability, with hepatitis A and E being responsible for the remaining.

 


Keywords: HIV, TB, hepatitis, viral, prevention and control, public health, vaccination

 

Download Publication

The Power of Antiretroviral Medicines — 90-90-90 Treatment for All. UNAIDS. (2017)

immage

Saving lives, preventing new HIV infections, preventing mother-to-child transmission of HIV, post-exposure prophylaxis for averting HIV infection, restoring respect and dignity to people living with HIV, pre-exposure prophylaxis for people at higher risk, preventing TB, TB-related deaths and TB transmission, restoring employment, reducing the number of children becoming orphans, and reducing maternal mortality.

 


Keywords: HIV, PMTCT, TB, PrEP, women, children

 

Download Infographic

HIV Drug Resistance Report 2017. WHO. (2017)

immage

This second HIVDR report provides an update on recent population levels of HIVDR covering the period 2014–2016. The report includes data from 16 nationally representative surveys from 14 countries estimating resistance in: adults initiating ART (PDR), children younger than 18 months newly diagnosed with HIV, and adults on ART (acquired HIV drug resistance or ADR).

To contextualize results from representative HIVDR surveys, the report is supported by systematic reviews of the published literature on PDR in adults, children and adolescents, and ADR in paediatric and adult populations. 


Keywords: HIV, ART, drug resistance, treatment, prevalence


Downloads

 

- HIV drug resistance report 2017

 

- Access policy brief: Tackling HIV drug resistance: trends, guidelines and global action

Global Priority List of Antibiotic-resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. WHO. (2017)

immage

The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention.


Keywords: new antibiotics, treatment, drugs, antibiotic resistance

 

Download Publication

Issue Brief: Using Competition Law to Promote Access to Medicines and Related Health Technologies in Low- and Middle-income Countries. UNDP. (2017)

immage

Competition law is an important policy tool that LMICs can use to protect consumer welfare and promote industrial and economic development. It aims to restrict unfair business practices, and promote quicker introduction and increased availability of health technologies. The issue brief highlights key aspects of using competition law to promote access to health technologies from UNDP’s landmark publication “Using Competition Law to Promote Access to Health Technologies: A guidebook for low- and middle-income countries.” The issue brief intends to be a resource for policymakers, national competition authorities, national procurement agencies, health authorities, civil society and other actors who have an interest in understanding the critical role of competition authorities in promoting access to health technologies.

 

Keywords: HIV, TB, LMICs, access, medicines, laws

 

Download Publication

The Journey of Universal Access to Antiretroviral Treatment in Thailand. UNDP, Ministry of Public Health and National Health Security Office. (2017)

immage

This book represents the consolidated knowledge and experience related to the policies and management of universal access to ART in Thailand. It aims to serve as an important tool to share knowledge with and advocate the policy of universal health coverage (UHC) to policymakers in the other developing nations that are working towards achieving UHC inclusive of the continuum of HIV and AIDS care services

 

Keywords: Thailand, HIV, PLHIV, ART, treatment, health system

 

 

Download Publication 

Pages

database
Highlighted publications
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal_National_Community_Led_HIV_Testing_Guidelines_2018.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_IBBS_PWID_PWUD_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_IBBS_FEW_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/DataHub_TB-HIV_Fact_Sheet_2018.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Monitoring_2018.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NSACP_Sri_Lanka_National_HIV_Communication_Strategy_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_Status_of_National_AIDS_Response_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V1_North-East_region_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V2_West_South_region_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V3_Northern_Central_Eastern_region_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_Annual_report_2016-17.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_Estimations_and_projections_of_HIV_AIDS_at_Sub-national_level_2016-2020.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_HIV_drug_resistance_report_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_on_public_health_response_to_pretreatment_HIV_drug_resistance_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_for_Managing_Advanced_HIV_Disease_and_Rapid_Initiation_of_ART_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_What_New_in_Treatment_Monitoring_Viral_Load_and_CD4_Testing_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_IBBS_2016-17.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_Mapping_Key_Populations_2015-16.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017_Data_2017_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_National_Strategic_Plan_on_HIV_and_AIDS_2016-2020.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_2017_Global_AIDS_Monitoring_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal-IBBS-FIDU-Kathmandu-valley-RI-2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_methods_for_deriving_estimates_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_Size_Estimation_of_Key_Affected_Populations_in_Philippines.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Assessment_of_Decentralization_of_ART_in_MMR_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-2016-prevention-gap-report_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Implementing_comprehensive_HIV_and_STI_programmes_with_transgender_people_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_cities_ending_the_aids_epidemic_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Philippines_2015_IHBSS_Fact_Sheets_Nov2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Consolidated_on_the_use_of_antiretroviral_drugs_for_treating_and_preventing_HIV_infection_2016.pdf
Calendar of events